Folate Decorated Nanomicelles Loaded with a Potent Curcumin Analogue for Targeting Retinoblastoma
- PMID: 28420213
- PMCID: PMC5489932
- DOI: 10.3390/pharmaceutics9020015
Folate Decorated Nanomicelles Loaded with a Potent Curcumin Analogue for Targeting Retinoblastoma
Abstract
The aim of this study was to develop a novel folate receptor-targeted drug delivery system for retinoblastoma cells using a promising anticancer agent, curcumin-difluorinated (CDF), loaded in polymeric micelles. Folic acid was used as a targeting moiety to enhance the targeting and bioavailability of CDF. For this purpose, amphiphilic poly(styrene-co-maleic acid)-conjugated-folic acid (SMA-FA) was synthesized and utilized to improve the aqueous solubility of a highly hydrophobic, but very potent anticancer compound, CDF, and its targeted delivery to folate overexpressing cancers. The SMA-FA conjugate was first synthesized and characterized by ¹H NMR, FTIR and DSC. Furthermore, the chromatographic condition (HPLC) for estimating CDF was determined and validated. The formulation was optimized to achieve maximum entrapment of CDF. The particle size of the micelles was measured and confirmed by dynamic light scattering (DLS) and transmission electron microscopy (TEM). Cytotoxicity studies were conducted on (Y-79 and WERI-RB) retinoblastoma cells. Results showed that the solubility of CDF could be increased with the newly-synthesized polymer, and the entrapment efficiency was >85%. The drug-loaded nanomicelles exhibited an appropriate size of <200 nm and a narrow size distribution. The formulation did not show any adverse cytotoxicity on a human retinal pigment epithelial cell (ARPE-19), indicating its safety. However, it showed significant cell killing activity in both Y-79 and WERI-RB retinoblastoma cell lines, indicating its potency in killing cancer cells. In conclusion, the folic acid-conjugated SMA loaded with CDF showed promising potential with high safety and pronounced anticancer activity on the tested retinoblastoma cell lines. The newly-formulated targeted nanomicelles thus could be a viable option as an alternative approach to current retinoblastoma therapies.
Keywords: 3,4-difluorobenzylidene curcumin (CDF); WERI-RB; Y-79; fluorocurcumin; folate-receptor targeting; nanomicelles; retinoblastoma; targeted drug delivery.
Conflict of interest statement
The authors declare no conflict of interest.
Figures
Similar articles
-
Nanoparticle-based delivery systems as emerging therapy in retinoblastoma: recent advances, challenges and prospects.Nanoscale Adv. 2023 Aug 15;5(18):4628-4648. doi: 10.1039/d3na00462g. eCollection 2023 Sep 12. Nanoscale Adv. 2023. PMID: 37705787 Free PMC article. Review.
-
Folic acid conjugated polymeric micelles loaded with a curcumin difluorinated analog for targeting cervical and ovarian cancers.Colloids Surf B Biointerfaces. 2017 Sep 1;157:490-502. doi: 10.1016/j.colsurfb.2017.06.025. Epub 2017 Jun 21. Colloids Surf B Biointerfaces. 2017. PMID: 28658642 Free PMC article.
-
Synthesis and characterization of folate decorated albumin bio-conjugate nanoparticles loaded with a synthetic curcumin difluorinated analogue.J Colloid Interface Sci. 2017 Jun 15;496:290-299. doi: 10.1016/j.jcis.2017.01.092. Epub 2017 Feb 14. J Colloid Interface Sci. 2017. PMID: 28236692
-
Hyaluronic Acid Engineered Nanomicelles Loaded with 3,4-Difluorobenzylidene Curcumin for Targeted Killing of CD44+ Stem-Like Pancreatic Cancer Cells.Biomacromolecules. 2015 Sep 14;16(9):3042-53. doi: 10.1021/acs.biomac.5b00941. Epub 2015 Aug 31. Biomacromolecules. 2015. PMID: 26302089
-
Advances in active targeting of ligand-directed polymeric nanomicelles via exploiting overexpressed cellular receptors for precise nanomedicine.RSC Adv. 2024 Jul 26;14(32):23520-23542. doi: 10.1039/d4ra04069d. eCollection 2024 Jul 19. RSC Adv. 2024. PMID: 39071479 Free PMC article. Review.
Cited by
-
Advancements in Nanosystems for Ocular Drug Delivery: A Focus on Pediatric Retinoblastoma.Molecules. 2024 May 11;29(10):2263. doi: 10.3390/molecules29102263. Molecules. 2024. PMID: 38792122 Free PMC article. Review.
-
An Update on Emergent Nano-Therapeutic Strategies against Pediatric Brain Tumors.Brain Sci. 2024 Feb 18;14(2):185. doi: 10.3390/brainsci14020185. Brain Sci. 2024. PMID: 38391759 Free PMC article. Review.
-
Nanoparticle-based delivery systems as emerging therapy in retinoblastoma: recent advances, challenges and prospects.Nanoscale Adv. 2023 Aug 15;5(18):4628-4648. doi: 10.1039/d3na00462g. eCollection 2023 Sep 12. Nanoscale Adv. 2023. PMID: 37705787 Free PMC article. Review.
-
Itraconazole and Difluorinated-Curcumin Containing Chitosan Nanoparticle Loaded Hydrogel for Amelioration of Onychomycosis.Biomimetics (Basel). 2022 Nov 21;7(4):206. doi: 10.3390/biomimetics7040206. Biomimetics (Basel). 2022. PMID: 36412734 Free PMC article.
-
Nanotechnology for Pediatric Retinoblastoma Therapy.Pharmaceuticals (Basel). 2022 Aug 31;15(9):1087. doi: 10.3390/ph15091087. Pharmaceuticals (Basel). 2022. PMID: 36145308 Free PMC article. Review.
References
-
- Di Fiore R., Drago-Ferrante R., D’Anneo A., Augello G., Carlisi D., De Blasio A., Giuliano M., Tesoriere G., Vento R. In human retinoblastoma Y79 cells okadaic acid-parthenolide co-treatment induces synergistic apoptotic effects, with PTEN as a key player. Cancer Biol. Ther. 2013;14:922–931. doi: 10.4161/cbt.25944. - DOI - PMC - PubMed
-
- Aerts I., Pacquement H., Doz F., Mosseri V., Desjardins L., Sastre X., Michon J., Rodriguez J., Schlienger P., Zucker J.M., et al. Outcome of second malignancies after retinoblastoma: A retrospective analysis of 25 patients treated at the Institut Curie. Eur. J. Cancer. 2004;40:1522–1529. doi: 10.1016/j.ejca.2004.03.023. - DOI - PubMed
-
- Boice J.D., Abramson D.H. Cancer incidence after retinoblastoma: Radiation dose and sarcoma risk. Surv. Ophthalmol. 1998;43:288–289. - PubMed
LinkOut - more resources
Full Text Sources
Other Literature Sources